1 / 15

Combine conference

Combine conference. R3 陳斯逸 /VS 孫銘希 Jan.8.2007. General data. ID: 1878644F Male 67 y/o Farmer. Brief history. Chief Complaint : Progressive malaise and sleepy for more than 3 months. Present illness : Progressive sleepy, drowsy, impaired recent memory since 3 months ago.

carsyn
Télécharger la présentation

Combine conference

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Combine conference R3陳斯逸/VS 孫銘希 Jan.8.2007

  2. General data • ID: 1878644F • Male • 67 y/o • Farmer

  3. Brief history • Chief Complaint: Progressive malaise and sleepy for more than 3 months. • Present illness: Progressive sleepy, drowsy, impaired recent memory since 3 months ago. Right limbs hemiparesis and clumsy since 2 days prior to admission-> 署立豐原醫院 Brain MRI: multiple brain lesion. Chest, Abdomen CT from other hospital: negative finding.

  4. Neurological examination • Arousable, but stupor. Incoherent speech. GCS level: E4V4M5-6. • Intact cranial nerve function • Muscle power: RUL/LUL: grade 3/5 • Pathological reflex: bilateral Babinski’s sign (+).

  5. Hospital course • Admission for second opinion • Tumor markers: all within normal range • CT guide navigation assisted biopsy was performed • Frozen section report: old hemorrhage • Permanent biopsy.

  6. Cavernous hemangioma • AKA: cavernoma, cavernous malformation, angioma • Benign vascular harmatoma consisting of irregular thick and thin walled sinusoidal vascular channels located within brain without interventing neural parenchyma.

  7. Cavernoma--Epidemiology • 1-5 cm in size. Multiple in 50 % cases. In White matter. • About 0.4-0.9% in population.Comprise 5-13% CNS vascular malformation • Mostly supratentorial, but 10-23% locates in posterior fossa with a predilection for the pons. • Sporadic or hereditary type. The hereditary type (familial type) may be inherited in AD pattern. It is more common in Hispanics. • J Neurosurg 95:825–832, 2001

  8. Presentation • Seizures (60%), Neurological deficit(50%), hemorrhage (20%), hydrocephalus. • Hemorrhage tend to occur in young group in familial than sporatic ones. Through repeated small hemorrhage in these lesions, they are rarely devastating. • In familial ones, CCM1(KRIT 1 gene) and CCM2 gene on Chromosome 7 had been demonstrated. • Risk of bleeding: 0.5%-1% (May be more frequent in basal ganglia, thalamus, spinal cord). Rebleeding: 4-10 % per year.

  9. Evaluation • Best detected in MRI best sequence: regular T2 : popcorn appearance. Gradient echo (GRE): Indian ink, blotch appearance. CT: heterogenous hyperdense (hemorrhage or calcification)without enhancement). • Non detectable on angiography( i.e. AOVM : angiographic occult venous malformation)

  10. Treatment • Accessible lesion with focal neurological deficit: surgically excision. • Do not response well to radiation therapy or radiosurgery. (But some reported it to reduce re-bleeding rate) • Conservative treatment: conservative management is recommended for patients harboring asymptomatic lesions without bleeding, especially if deeply located, in eloquent areas, or in patients with multiple lesions(1)

  11. Surgical indications include (1) progressive neurologic deficits; (2) grave neurologic deficits like coma, cardiopulmonary instability; (3) overt acute or subacute hemorrhage on MRI either inside or outside cavernous malformations with mass effect;(4) cavernoma or hematoma 2 mm from brain stem surface. • Timing of surgery should be decided at about 1-2 week, the time after edema subsided and before hematoma resorption and gliosis development. (2)

  12. J. Neurosurg. / Volume 95 / November, 2001

  13. Reference 1. Neurosurg Focus 21 (1):E11, 2006 2. J. Neurosurg. / Volume 95 / November, 2001 3. Surgical Neurology 2003(59) 444-454

  14. Thank you for attention.

More Related